Last updated on February 2019

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)


Brief description of study

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

Clinical Study Identifier: NCT03302234

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Hospital Nacional Guillermo Almenara Irigoyen ( Site 0705)
La Victoria, Peru
1.55miles
  Connect »

Study Coordinator

Clinica Internacional Sede San Borja ( Site 0701)
Lima, Peru
2.73miles
  Connect »

Study Coordinator

Hospital Nacional Cayetano Heredia ( Site 0706)
Lima, Peru
2.73miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.